Ideal Medical Technologies

What Ideal Medical Technologies does

Ideal Medical Technologies (IMT) is an Asheville, North Carolina-based medical device company developing the FUSION system, an AI-based closed-loop glucose control platform (described as an artificial pancreas) intended for use in hospital intensive care units. The system integrates continuous glucose monitoring hardware (Dexcom G6 or EIRUS CGM), a Teguar medical computer running proprietary AI control software, and Enovate-powered medical cart housing syringe pumps to autonomously adjust intravenous insulin and dextrose infusion rates every 5-10 minutes. The proprietary algorithms mimic native pancreas and liver glucose control mechanisms derived from a peer-reviewed 2010 publication, and in a first-in-human study (May 2023, 7 participants) the system achieved 87.8% time in range 70-180 mg/dL with only 0.2% time below range and a coefficient of variation of 19.4%.

The company's regulatory pathway is well-defined: the FDA designated FUSION as a Breakthrough Medical Device in March 2019, multiple IDE approvals have been secured (March 2021, February 2025 software update, December 2025 new IDE), and a 2023 pre-submission meeting confirmed commercial clearance will be sought via the 510(k) pathway. The company has received $1.9M in non-dilutive funding through an NIH SBIR Phase II grant (June 2022), supplemented by a $200,000 raise in May 2020; no venture or private equity capital has been disclosed. Founder Dr. Leon DeJournett (CEO) leads with over 30 years of ICU experience, supported by CTO Jeremy DeJournett and clinical collaboration with Dr. Francisco Pasquel of Emory University, who led the first-in-human study.

IMT's planned go-to-market targets hospital ICU departments with a B2B enterprise sales model selling the complete FUSION system (hardware plus software) likely via hospital procurement and Group Purchasing Organization (GPO) contracts. Pricing is not publicly disclosed and the company remains pre-revenue pending 510(k) clearance. Future product iterations are described as potentially expanding to control additional ICU parameters including osmolality, intravascular volume status, and blood pressure.

Name

Ideal Medical Technologies

Legal name

Ideal Medical Technologies, Inc.

Website

https://idealmedtech.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Ideal Medical Technologies develops the FUSION system, an AI-based closed-loop glucose control platform for hospital ICU patients that autonomously adjusts intravenous insulin and dextrose infusions using continuous glucose monitoring data, targeting B2B sales to hospital intensive care units.

Ownership category

akta.pro rank

Product category

Medical Devices (ICU Glucose Control)

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)

akta.pro secondary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Closed-loop glucose control
• Artificial pancreas systems
• ICU medical devices
• AI glucose management
• Automated insulin delivery

Headquarters

HQ city

Asheville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

1. FUSION System Hardware and Software: Medical device combining proprietary AI software with hardware components (Dexcom G6 CGM, medical computer, syringe pumps, powered medical cart). Revenue will come from sale of the complete FUSION system to hospital ICUs.
2. AI Glucose Control Software Licensing: Proprietary AI-based glucose control software forms the core technology, potentially licensed separately or bundled with hardware. The software received Breakthrough Medical Device designation from FDA in March 2019.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Ideal Medical Technologies develops and plans to commercialize the FUSION System, an AI-driven, closed-loop glucose control system (artificial pancreas) designed for hospital ICU patients. The system integrates continuous glucose monitoring (Dexcom G6 or EIRUS CGM) with proprietary AI control software running on approved medical computing hardware, autonomously adjusting intravenous insulin and dextrose infusion rates every 5-10 minutes to maintain tight glucose control. Revenue is expected from sale of the complete FUSION system to hospital ICUs, with potential licensing of the core AI software.

Product overview

Ideal Medical Technologies offers a single unified product: the FUSION System, an artificially intelligent closed-loop glucose control system (artificial pancreas) designed for ICU patients. The FUSION System is a modular platform that integrates continuous glucose monitoring (Dexcom G6 or EIRUS CGM) with AI-based control software running on approved medical computing hardware, connected to syringe pumps for automated insulin and dextrose delivery. The system operates autonomously, requiring only 20 minutes of daily nursing time versus the current standard of care that requires 1-2 hours per patient per day.

Differentiator

Problem solved

Functional benefit

Brands

• FUSION: An artificially intelligent, hospital-based, closed-loop glucose control system (artificial pancreas) for ICU patients that automatically adjusts intravenous insulin and dextrose infusions.

Products and services

• FUSION System An artificially intelligent, hospital-based, closed-loop glucose control system (artificial pancreas) for ICU patients. The system continuously reads glucose values from a continuous glucose monitor (e.g., Dexcom G6) and uses proprietary AI-based expert rule software to autonomously adjust intravenous insulin and dextrose infusion rates every 5-10 minutes. Indicated for ICU patients requiring tight glucose control, including those with diabetes and stress-induced hyperglycemia.

Quantifiable outcome

• Reduces nursing time from 1-2 hours to 20 minutes per patient per day
• +7 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability3 records

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Emory UniversitycoreStrategic or Co-development PartnerCollaborative agreement with Emory University for clinical studies of FUSION system. Clinical studies led by Dr. Francisco Pasquel, one of the world's foremost authorities on inpatient glucose control. First-in-human study performed at Emory under FDA IDE approval.
• VelentiumcoreTechnology or IntegrationSoftware experts at Velentium (chosen OEM) worked with IMT to ensure FUSION system software documentation adheres to new FDA standards released in June 2023. Velentium is responsible for transferring FUSION device specifications to contract manufacturer for commercial grade version.
• North Carolina Biotechnology CenterminorStrategic or Co-development PartnerListed as collaborator on company website, indicating regional partnership for biotech development support in North Carolina.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Insulet: Insulet's Omnipod 5 is an automated insulin delivery system for outpatient diabetes management. It shares the AID/closed-loop category with FUSION but targets a different care setting.
• Tandem Diabetes Care: Tandem Diabetes Care markets the t:slim X2 with Control-IQ, an automated insulin delivery system for outpatient use. It is comparable to FUSION as a closed-loop insulin delivery technology, though serving the outpatient diabetes market rather than the ICU.
• Beta Bionics: Beta Bionics developed the iLet bionic pancreas, an automated insulin delivery system. While focused on outpatient diabetes rather than ICU use, it shares the artificial pancreas / closed-loop insulin delivery technology category with FUSION.

Broad incumbents

• Medtronic: Medtronic offers the MiniMed 780G, an outpatient artificial pancreas system, and is a dominant player in insulin pumps and CGM-integration. While not focused on the ICU, its diabetes franchise and resources could expand into inpatient automated glucose control.
• Abbott Diabetes Care: Abbott's FreeStyle Libre is the global CGM market leader. While primarily a CGM and broader diagnostics incumbent, its hospital-grade CGM offerings overlap with the continuous glucose monitoring layer that FUSION depends on.

Direct peers

• Glytec: Glytec offers the eGlycemic Management System, a software-as-a-medical-device platform for insulin dosing in hospitals. It directly competes with FUSION in the hospital glucose management category, although Glytec's offering is currently software-guided rather than fully closed-loop/autonomous.
• Admetsys: Admetsys develops an automated insulin dosing system for hospital and surgical ICU patients. It is the most direct competitor to Ideal Medical Technologies, also targeting fully autonomous glucose control in the inpatient ICU setting with similar regulatory positioning.

Others

• Dexcom: Dexcom manufactures the G6 CGM that FUSION integrates with as a glucose input. It is an enabling technology partner/supplier rather than a direct competitor, but a key ecosystem dependency for FUSION's product architecture.

Market position

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ideal Medical Technologies